Mirum Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Mirum Pharmaceuticals, Inc. (MIRM) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value of $248.56 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $248.56M.
- 2026-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $95.70M.
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $94.75M.
- 2025-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $97.00M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2026-06-30 | $248.56M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $95.70M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $94.75M 10-K · filed 2026-02-25 |
| 2025-09-30 | $97.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $97.78M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $86.76M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $70.34M 10-K · filed 2025-02-26 |
| 2024-09-30 | $70.80M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $62.20M 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |